Allakos, Inc.
975 Island Drive, Suite 201
Redwood City
CA
94065
United States
Tel: 650-597-5002
Website: https://www.allakos.com/
Email: info@allakos.com
About Allakos, Inc.
We are a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases.
Our lead program is AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Our initial clinical focus is eosinophilic gastritis, an inflammatory disease of the gastrointestinal tract. We are also conducting clinical trials for other mast cell and eosinophil-driven diseases.
37 articles with Allakos, Inc.
-
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms
5/24/2021
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD)
-
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
5/10/2021
Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, reported financial results for the first quarter ended March 31, 2021 and provided a business update.
-
Allakos Appoints Baird Radford as Chief Financial Officer
4/19/2021
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial Officer.
-
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
3/30/2021
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting
-
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/1/2021
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.
-
Allakos Appoints Natalie Holles to its Board of Directors
12/22/2020
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide
-
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
11/2/2020
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020 Virtual Annual Scientific Meeting.
-
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
10/27/2020
Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020. The preliminary financial results are subject to finalization of the Company’s customary quarterly financial close process. Allakos estimates that net loss will be between $40.0 million and $50.0 million fo
-
Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed
10/26/2020
45% (181/405) ofsymptomatic patients biopsied with chronic functional gastrointestinal symptoms met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis
-
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
10/26/2020
Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustainedeosinophil suppressionsupporting once monthly dosing
-
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
10/21/2020
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-blind, placebo-controlled Phase 2 study of lirentelimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis (ENIGMA) in the New England Journal of Medicine (NEJM). All AK002 dose a
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
6/3/2020
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis -- -- Top-line safety and efficacy results from both studies expected in the second half of 2021 --
-
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020
5/21/2020
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of two oral abstract presentations at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress being held virtually from June 6 to 8, 2020. The following virtual oral abstract presentations will be available starti
-
Allakos Reports First Quarter 2020 Financial Results
5/11/2020
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020. First Quarter 2020 Financial Results Research and development expenses were $18.3 million in the first quarter of 2020 as compared to $15.1 million in the same period in 2019, an increase of $3.2 mil
-
Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting
5/11/2020
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of an oral presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. The virtual presentation will take place on May 16, 2020 at 6:00pm ET. The abstract is currently available on the ASCRS
-
Allakos Announces Positive Interim Results from an Open-Label Extension Study of Antolimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis
5/4/2020
-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment -- REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported results from a long-term open-label extension (OLE) study of antolimab for the tre
-
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting
4/21/2020
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting. The presentations will take place during the DDW Annual Meeting being held virtually from May 2 to 5, 2020. Access to all accepted abstracts,
-
Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
3/24/2020
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported the initiation of three clinical studies of antolimab: a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD), a Phase 2/3 study in eosinophilic esophagitis (EoE), and a Phase 1 study of subcutaneously administered antolimab in healthy volunteers.
-
Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease
3/24/2020
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported results from a Phase 1 study evaluating the safety and efficacy of antolimab for the treatment of patients with mast cell gastrointestinal disease.